These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21569005)

  • 21. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
    Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
    Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.
    Scielzo C; Ghia P; Conti A; Bachi A; Guida G; Geuna M; Alessio M; Caligaris-Cappio F
    J Clin Invest; 2005 Jun; 115(6):1644-50. PubMed ID: 15931393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders.
    Lúcio PJ; Faria MT; Pinto AM; da Silva MR; Correia Júnior ME; da Costa RJ; Parreira AB
    Haematologica; 1998 Feb; 83(2):104-11. PubMed ID: 9549920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells.
    Zarcone D; De Rossi G; Tenca C; Marroni P; Mauro FR; Cerruti GM; Albi N; Fiorucci S; Velardi A; Grossi CE
    Haematologica; 1998 Dec; 83(12):1088-98. PubMed ID: 9949626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia.
    Boonstra JG; von't Veer MB; Gratama JW
    J Biol Regul Homeost Agents; 2004; 18(3-4):340-6. PubMed ID: 15786702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
    Ahmad E; Steinberg SM; Goldin L; Hess CJ; Caporaso N; Kreitman RJ; Wiestner A; Wilson W; White T; Marti G; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2008 Jul; 74(4):221-6. PubMed ID: 18431797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia.
    Eisele L; Haddad T; Sellmann L; Dührsen U; Dürig J
    Leuk Res; 2009 Jun; 33(6):775-8. PubMed ID: 18922578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells.
    Vaisitti T; Serra S; Pepper C; Rossi D; Laurenti L; Gaidano G; Malavasi F; Deaglio S
    Leukemia; 2013 Apr; 27(5):1177-81. PubMed ID: 22955446
    [No Abstract]   [Full Text] [Related]  

  • 30. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
    Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of VH genes mutation status for prognosis of CLL patients.
    Bilous N; Abramenko I; Kryachok I; Bazyka D; Chumak A; Bebeshko V
    Exp Oncol; 2005 Dec; 27(4):325-9. PubMed ID: 16404355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.
    Deaglio S; Vaisitti T; Zucchetto A; Gattei V; Malavasi F
    Semin Cancer Biol; 2010 Dec; 20(6):416-23. PubMed ID: 20817095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD38 at the junction between prognostic marker and therapeutic target.
    Deaglio S; Aydin S; Vaisitti T; Bergui L; Malavasi F
    Trends Mol Med; 2008 May; 14(5):210-8. PubMed ID: 18403265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance.
    Zucchetto A; Bomben R; Dal Bo M; Bulian P; Benedetti D; Nanni P; Del Poeta G; Degan M; Gattei V
    Leukemia; 2006 Mar; 20(3):523-5; author reply 528-9. PubMed ID: 16408095
    [No Abstract]   [Full Text] [Related]  

  • 35. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Strati P; Parikh SA; Chaffee KG; Achenbach SJ; Slager SL; Call TG; Ding W; Jelinek DF; Hanson CA; Kay NE; Shanafelt TD
    Br J Haematol; 2017 Jul; 178(1):99-105. PubMed ID: 28386906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome.
    Rossi D; Bodoni CL; Zucchetto A; Rasi S; De Paoli L; Fangazio M; Rossi FM; Ladetto M; Gattei V; Gaidano G
    Am J Hematol; 2010 Aug; 85(8):619-22. PubMed ID: 20578200
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiogenic factor VEGF and its relationship with biological prognostic markers in chronic lymphocytic leukemia.
    Ayad MW; El Naggar AA
    Egypt J Immunol; 2010; 17(1):59-71. PubMed ID: 22053610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.
    Dal Bo M; Tissino E; Benedetti D; Caldana C; Bomben R; Poeta GD; Gaidano G; Rossi FM; Bulian P; Zucchetto A; Gattei V
    Curr Cancer Drug Targets; 2016; 16(8):659-668. PubMed ID: 27514846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals.
    Elizabeth S; Aidan K; David OB; Deirdre W; Sarah B; Emer A; Kanthi P; Crotty GM; Aileen W; Michelle C; Ruth C; Hilary O; Ashique K; Bacon CL; Emily S; McElligott AM; Fiona Q; Elisabeth V; Carmel W
    Eur J Haematol; 2022 Nov; 109(5):441-446. PubMed ID: 35776688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia.
    Shehata M; Demirtas D; Schnabl S; Hilgarth M; Hubmann R; Fonatsch C; Schwarzinger I; Hopfinger G; Eigenberger K; Heintel D; Porpaczy E; Vanura K; Hauswirth A; Schwarzmeier JD; Gaiger A; Stilgenbauer S; Hallek M; Bilban M; Jäger U
    Leukemia; 2010 Dec; 24(12):2122-7. PubMed ID: 20966934
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.